Applied DNA Sciences

Applied DNA Sciences, Inc. engages in developing and marketing technologies to produce and detect deoxyribonucleic acid. It operates through the following segments: Therapeutic DNA Production, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production segment consists of the manufacture of DNA for use in nucleic acid-based therapeutics. The MDx Testing Services segment is involved in performing and developing clinical molecular diagnostic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment includes manufacture and detection of DNA for industrial supply chain security services. The company was founded in 1983 and is headquartered in Stony Brook, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Applied DNA Sciences reports strong Q1 results and eyes revenue diversification

Applied DNA Sciences demonstrated robust revenue growth and operational improvements in Q1 2023, driven by key revenue streams and cost management.
While facing financial challenges and dependency on key projects for guidance, the company is strategically positioned for growth and innovation.
Opportunities in nucleic acid therapies, strategic partnerships, and revenue diversification present a promising outlook for Applied DNA Sciences.

Applied DNA Sciences adapts focus to genomics amid revenue challenges

Applied DNA Sciences faced revenue challenges in Q2 2023 but showcased resilience through strategic focus on pharma genomics testing and DNA tagging solutions.
The company's emphasis on efficiency in mRNA manufacturing and pursuit of acquisitions signal a proactive approach to enhancing market competitiveness and technological capabilities.
While financial challenges persist, opportunities in genetic testing and compliance solutions position Applied DNA Sciences for future growth and market leadership.

Applied DNA Sciences reports revenue decline and operational challenges

Applied DNA Sciences faced challenges in revenue decline and increased operating expenses in Q3 2023, leading to an operating loss and concerns about its financial sustainability.
Despite these challenges, the company demonstrated strengths in enhancing mRNA initiatives through the Spindle Biotech acquisition and Linea IVT platform, as well as continued growth in supply chain traceability.
Opportunities lie in expanding partnerships with evaluation customers, leveraging the Linea IVT platform's capabilities, and exploring new revenue streams in DNA tagging applications.

Applied DNA Sciences reports Q4 revenue decline, focuses on growth

Applied DNA Sciences faced a challenging quarter with declining revenues and operating losses, but maintained a focus on innovation and growth.
The company's strategic strengths lie in biotherapeutic manufacturing, successful acquisitions, and plans for revenue expansion through the Linea IVT platform.
However, challenges such as Nasdaq compliance issues and financial pressures require careful management and strategic decision-making.
Opportunities for revenue growth and market expansion exist through customer relationships, product development, and addressing regulatory requirements.

Applied DNA Sciences tackles financial challenges while eyeing revenue growth

Applied DNA Sciences faces challenges with declining revenues and profitability, necessitating a focus on cost management and revenue generation to improve financial health.
Despite financial pressures, the company's strategic strengths lie in innovative product development, quality control measures, and efforts to enhance operational efficiency.
Opportunities for revenue growth exist through the commercialization of Linea IVT platform, international expansion, and partnerships, signaling potential for market expansion and increased customer adoption.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Applied DNA Sciences, Inc. engages in developing and marketing technologies to produce and detect deoxyribonucleic acid. It operates through the following segments: Therapeutic DNA Production, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production segment offers DNA detection via PCR to provide and develop clinical molecular diagnostics and genetic testing services. The MDx Testing Services segment is involved in performing and developing clinical molecular diagnostic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment includes manufacture and detection of DNA for industrial supply chain security services. The company was founded in 1983 and is headquartered in Stony Brook, NY.

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced the receipt of a purchase order for its Linea™ COVID-19 Assay Kit (the “Assay Kit”) and consumables to conduct 10,000 tests under a Master Services Agreement with an existing customer. The Company expects to deliver most of the purchase order in the current fiscal quarter ending March 31, 2021 with the balance to be d

Applied DNA Receives Blanket Purchase Order for Linea™ COVID-19 Assay Kits for 10,000 Tests

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Launches Selective Genomic Surveillance Screening Platform for SARS-CoV-2 Variant Detection and Tracking.

Applied DNA Launches Linea™ COVID-19 Selective Genomic Surveillance™ Mutation Panel to Boost SARS-CoV-2 Variant Detection and Tracking Nationally

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, will be participating in the following virtual investor conferences. March 9 – 10, 2021 – Dr. James A. Hayward, president and CEO, will present a company overview at the H.C. Wainwright Global Life Sciences Virtual Conference. Dr. Hayward and Beth Jantzen, chief financial officer, will also hold virtual investor meet

Applied DNA to Participate in Upcoming Conferences

STONY BROOK, N.Y. & ROME--(BUSINESS WIRE)---- $APDN #COVID19--If the veterinary vaccine candidate demonstrates effectiveness, the two companies intend to apply to USDA to enable commercial vet sales under APHIS.

Applied DNA and Evvivax Initiate Phase I of Clinical Trial to Evaluate LinearDNA™ COVID-19 Vaccine Candidate for Feline Veterinary Market

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #DSCSA--Newly granted patent has applicability in the DNA tagging of pharmaceutical, nutraceutical and personal care excipients.

Applied DNA Granted U.S. Patent Covering Methods of Utilizing DNA Tagged Submicron Particles for Authentication

STONY BROOK, N.Y. & NEW YORK--(BUSINESS WIRE)---- $APDN #COVID19--NYC-based LIM College joins other education institutions relying on Applied DNA's safeCircle service to ensure a safe learning environment.

Applied DNA to Provide Back-To-Campus COVID-19 Surveillance Testing to LIM College

Applied DNA Sciences, Inc. (APDN) CEO James Hayward on Q1 2021 Results - Earnings Call Transcript

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Reports First Fiscal Quarter 2021 Revenues at Upper End of Guided Range

Applied DNA Reports First Fiscal Quarter 2021 Revenues at Upper End of Guided Range

STONY BROOK, N.Y. & PARSONS, Kansas--(BUSINESS WIRE)---- $APDN #COVID19--Linea(TM) COVID-19 Assay Kit utilized in genomic surveillance mode detects first instance of SARS-CoV-2 B.1.1.7 (UK) variant in Kansas.

Applied DNA and Cytocheck Detect First Instance of SARS-CoV-2 B.1.1.7 Variant in Kansas

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ: APDN) announced today that it will report fiscal 2021 first quarter financial results after market close on Thursday, February 11, 2021. The Company's management will discuss the results during a conference call and simultaneous webcast at 4:30 p.m. ET that same day. Presentation slides will also be posted to the ‘IR Calendar' section of the Company's corporate website and embedded into the live webcast. Conference Call and

Applied DNA Schedules Fiscal 2021 First Quarter Financial Results Conference Call and Webcast for Thursday, February 11, 2021

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--"Our veterinary vaccine program is a cost- and time-efficient path to commercializing our COVID-19 vaccine development work."

Applied DNA Achieves Program Milestone in Development of Linear DNA Veterinary COVID-19 Vaccine

Applied DNA Sciences (APDN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Applied DNA Sciences (APDN) Report Negative Q1 Earnings? What You Should Know

TORONTO--(BUSINESS WIRE)--TruTrace Technologies, Inc. (CSE: TTT) (“TruTrace” or the “Company”), developer of a fully-integrated blockchain platform for the legal cannabis, food and pharmaceutical industries, today announced the signing of a definitive agreement with Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, to approach the cannabis industry with an integrated solution comprised of Applied DNA's CertainT® platf

TruTrace Technologies™ and Applied DNA Unveil Complete Cannabis Product Validation and Authentication Solution

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced the signing of a definitive agreement with TruTrace Technologies, Inc. (CSE: TTT) (“TruTrace”), developer of a fully-integrated blockchain platform for the legal cannabis, food and pharmaceutical industries, to approach the cannabis industry with an integrated solution comprised of Applied DNA's CertainT® platform and

Applied DNA and TruTrace Technologies™ Unveil Complete Cannabis Product Validation and Authentication Solution

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced the promotion of Chief Information Officer Judith Murrah to the role of Chief Operating Officer effective immediately. The promotion formalizes Ms. Murrah's expanding range of responsibilities that includes the development of key customer and partner relationships, QA oversight, and operations management. Ms. Murrah h

Applied DNA Promotes Judith Murrah to Chief Operating Officer

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that its Linea™ COVID-19 Assay Kit (the “Assay Kit”) identified COVID-19 positive samples that are variants distinct from the wild-type virus that has dominated the U.S. in the pandemic until now. The variants were identified as part of the Company's safeCircleTM pooled surveillance testing service, which is powered b

Applied DNA Linea™ COVID-19 Assay Kit Demonstrates Effectiveness with Detection of Multiple SARS-CoV-2 Variants During Recent Surveillance Testing

Applied DNA Sciences (NASDAQ: APDN) shares are trading higher on reports the U.K. COVID strain could become the dominant strain in the U.S. The FDA last week reported the company's test is sensitive to the U.K. variant.

Why Applied DNA Sciences Is Up 30% Today

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ:APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that its safeCircle™ pooled surveillance testing service has seen a 158% increase in the daily average number of tests performed to date in January 2021 compared to December 2020. The increase is chiefly the result of the scale-up of certain testing contracts and from the acquisition of new clients. Launched in the fou

Applied DNA Provides Business Update on COVID-19 Diagnostics and Testing

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today the closing of its previously announced registered direct offering with a group of institutional investors of 1,810,000 shares of common stock at a price of $8.30 per share, priced at-the-market under Nasdaq rules, resulting in total gross proceeds of approximately $15 million, before deducting the placement agent's f

Applied DNA Announces Closing of $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today that it has entered into a securities purchase agreement with certain institutional investors, providing for the purchase and sale of 1,810,000 shares of common stock at a price of $8.30 per share, priced at-the-market under Nasdaq rules, in a registered direct offering, resulting in total gross proceeds of approximat

Applied DNA Announces Pricing of $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Applied DNA Sciences (NASDAQ: APDN) shares are trading higher after the U.S. Food and Drug Administration published communication that identifies the company's Linea COVID-19 Assay Kit as one of only two tests marketed under the FDA's Emergency Use Authorization. The tests are potentially able to identify certain SARS-CoV-2 mutations, including a mutation found in the U.K.

Why Applied DNA Sciences Is Up 80% Today

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today that the U.S. Food and Drug Administration (FDA) published a safety communication (the “Communication”) that identifies the Company's Linea™ COVID-19 Assay Kit (the “Assay Kit”) as one of only two tests marketed under the FDA's Emergency Use Authorization (EUA) that are potentially able to identify certain SARS-CoV-2

U.S. FDA Lists Applied DNA's Linea™ COVID-19 Assay Kit as 1 of Only 2 EUA-Authorized Tests Able to Detect S-Gene Mutation Found in SARS-CoV-2 U.K. Variant (B.1.1.7)

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced that Dr. James A. Hayward, president and CEO, will participate in a fireside chat at the virtual H.C. Wainwright BIOCONNECT 2021 Conference to be held January 11-14, 2021. The fireside chat will be hosted by Yi Chen, Managing Director, H.C. Wainwright Equity Research, and Applied DNA covering analyst. The fireside chat will

Applied DNA to Participate in the H.C. Wainwright BIOCONNECT 2021 Conference

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today that it expects revenues for the first fiscal quarter of 2021 ended December 31, 2020, to be in the range of $1.3 million to $1.6 million compared to revenues of $314,000 in the fourth quarter of fiscal 2020. The strong sequential growth in quarterly revenues is driven principally by demand for safeCi

Applied DNA Announces Preliminary Estimated First Fiscal Quarter 2021 Revenues in the Range of $1.3 Million to $1.6 Million

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today that its wholly-owned subsidiary, Applied DNA Clinical Laboratories, LLC (ADCL) has entered into a reseller and sales referral partnership with CLEARED4, a field-proven, New York-based provider of return-to-work health safety solutions. Under the terms of the partnership, ADCL can resell subscriptions

News for Applied DNA Sciences Stock (APDN)